ArticleJournal of the American Heart Association2025
Treatment Response and Survival in Methamphetamine-Associated Pulmonary Arterial Hypertension.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Methamphetamine-Associated Pulmonary Arterial Hypertension in a Japanese Pulmonary Hypertension Referral Center.Circulation reports · 2026Article
- Marked Improvement in Pulmonary Arterial Hypertension in 3 Patients with a History of Amphetamine-like Drug use and Comorbidities.The open respiratory medicine journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundMethamphetamine-associated pulmonary arterial hypertension (Meth-PAH) represents a growing subset of PAH. Relative to idiopathic PAH (iPAH), it is unknown whether patients with Meth-PAH treated with continuous prostacyclin have similar outcomes and treatment response. The aims of this analysis are to evaluate survival, response to therapy, and right ventricle function in similarly treated patients with Meth-PAH and iPAH.
methodsA prospective protocolized cohort of 138 incident patients (64 Meth-PAH, 74 iPAH) was followed longitudinally, with all patients being treatment-naïve at baseline. Hemodynamic assessments, cardiac imaging, and response to therapy were evaluated. A standardized therapeutic approach involving parenteral subcutaneous treprostinil was applied. Survival was analyzed using Kaplan-Meier and Cox regression.
resultsBoth groups had similarly advanced PAH at presentation. Improvement in hemodynamics and reduction in European Respiratory Society risk scores were seen over the course of follow-up in both groups. Twenty-nine of 64 (45%) Meth-PAH and 51/74 (69%) of iPAH were initiated on parenteral prostacyclin. During treatment, only 4 patients (2 iPAH and 2 meth-PAH) were taken off treprostinil because of safety concerns. Transplant-free survival was 54/64 (84.4%) for meth-PAH over a mean follow-up time of 46 months and 54/74 (72.9%) for iPAH over a mean follow-up time of 67 months. Additionally, continued methamphetamine use did not adversely affect disease progression or mortality.
conclusionsAmong Meth-PAH patients treated with an aggressive parenteral prostacyclin strategy, there is not a large difference in mortality and treatment response to iPAH. Further research is warranted to explore the long-term effects of methamphetamine use on PAH pathogenesis and outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.